102 results about "Lymphatic system" patented technology

Disclosed herein are methods for inducing an immunological CTL response to an antigen by sustained, regular delivery of the antigen to a mammal so that the antigen reaches the lymphatic system. Antigen is delivered at a level sufficient to induce an immunologic CTL response in a mammal and the level of the antigen in the mammal's lymphatic system is maintained over time sufficient to maintain the immunologic CTL response. Also disclosed is an article of manufacture for delivering an antigen that induces a CTL response in an animal.

The present invention is directed to a method for delivering cytokines to the central nervous system and the lymphatic system by way of a tissue innervated by the trigeminal nerve and / or olfactory nerve. Cytokines include tumor necrosis factors, interleukins, interferons, particularly interferon-β and its muteins such as IFN-βser17. Such a method of delivery can be useful in the treatment of central nervous system disorders, brain disorders, proliferative, viral, and / or autoimmune disorders such as Sjogren's disorder.

Disclosed herein are methods for inducing an immunological CTL response to an antigen by sustained, regular delivery of the antigen to a mammal so that the antigen reaches the lymphatic system. Antigen is delivered at a level sufficient to induce an immunologic CTL response in a mammal and the level of the antigen in the mammal's lymphatic system is maintained over time sufficient to maintain the immunologic CTL response. Also disclosed is an article of manufacture for delivering an antigen that induces a CTL response in an animal.

Embodiments of the present invention are directed to systems, apparatuses, devices and methods for improving, modifying and / or stabilizing pharmacokinetic and / or pharmacodynamic profile of a drug infused into the tissue by a catheter and absorbed into the blood or lymphatic system. In some embodiments, infusion sets provide fluid and electrical connection between a catheter assembly / treatment element and at least one of a fluid source and a second source.

A composition is provided accompanying nonoparticles having diameters in the range of about 100 to 800 nanometers with hollow cores and outer shells with mechanical properties such that they rupture on exposure to predetermined ultrasound energy. The composition is useful for identifying sentinel lymph nodes.

A microfluidic-based platform with cultured three-dimensional tissues simulates major human physiological systems for rapid evaluation of individual drugs prior to clinical testing or for personalized medical applications. The platform integrates the circulatory and lymphatic systems in a physiologically correct manner. The physiological systems may be simulated in the platform by microfluidic tissue culture devices which accommodate various tissues and provide integrated microvascular and lymphatic systems. Biomimetic nanofiber meshes or microfiber structures may be used to provide the cells with a physiologically relevant substrate. Each device may have an on-board detection system utilizing optical fiber bundles for microarray multiplexing of biomarkers, label-free SERS measurement of drugs, and microendoscopic confocal imaging of cells and tissues.

The present invention is directed to an implantable device comprising a biocompatible and biodegradable matrix impregnated with a bioactive complex suitable for selectively targeting the lymphatic system, wherein the bioactive complex comprises one or more particle forming materials and one or more bioactive agents. The invention is further directed to methods of using and the process of preparing, the implantable device.

A method, system and device for enhancing muscle training and performance by accelerating blood flow to the muscles and enhancing flow in the lymphatic system, incorporating mechanical stimulation and in some cases electrical stimulation of the muscle. A muscle recovery apparatus includes: an active compression device and an electrical stimulation device, where the active compression device is configured to be disposed about a user's muscle and to mechanically compress the user's muscle to facilitate muscle recovery, and where the electrical stimulation device is coupled to an inner surface of the active compression device, such that the electrical stimulation device can be placed in contact with the user to electrically stimulate the user's muscle.

The invention relates to a lenalidomide derivative and a use thereof as a medicine, and in particular relates to a compound shown as a formula (I), a solvate, a hydrate, a stereoisomer or pharmaceutically acceptable salt thereof. The invention further relates to a pharmaceutical composition comprising the compound, and the use of the compound in preparing medicines for preventing or treating malignant tumors, in particular malignant tumors in the blood-lymphatic system. Compared with lenalidomide, the compound provided by the invention has a longer half-life period and can be used for preparing long-acting preparations.

A composition and method for treatment and / or prophylaxis of stressed-induced conditions and a method of forming the composition are disclosed. The composition includes hyaluronic acid and superoxide dismutase configured to mitigate denaturing of the superoxide dismutase in a digestive track of an animal. Mitigating the denaturing of the superoxide dismutase allows simultaneous administration of both the hyaluronic acid and superoxide dismutase to the circulatory and lymph systems of an animal.

An improved apparatus and method of body contouring and skin conditioning for the treatment of conditions such as lymphoedema by producing vibrations in the subcutaneous layers of fat. The apparatus includes a cup which engages the patient's skin surface and a vacuum source which provides suction and a pulsating movement against the skin's surface, mimicking the movement of the lymphatic system and flushing out toxins, fat layers and trapped fluid from the area.

Techniques are provided for use by a pacemaker or other implantable medical device for detecting and tracking trends in cardiopulmonary fluid transfer rates—such as heart-to-lung fluid perfusion rates and lung-to-lymphatic system fluid excretion rates—and for detecting heart failure, dyspnea or other cardiopulmonary conditions. In one example, the device periodically measures transthoracic admittance values. A first exponential time-constant (k1) is determined using curve-fitting from admittance values obtained while the patient is in a sleep posture. Time-constant k1 is representative of the fluid perfusion rate. A second exponential time-constant (k2) is determined based on admittance values obtained while the patient is standing / walking / sitting. The second exponential time-constant (k2) is representative of the fluid excretion rate from the lungs. The device then detects trends, if any, in the time-constants (or in “DC” baseline values) to detect or predict medical conditions such as an imminent heart failure exacerbation.

The invention discloses a biological self-assembly nanometer crystal injection agent composition with a lympha targeted function and an administration mode for targeting a lymphatic system by using a biological self-assembly nanometer crystal injection agent. A recipe composition is prepared from 0.05 to 5 percent of mitoxantrone and mitoxantrone salt, 0.1 to 10 percent of osmotic pressure regulating agents, 0.001 to 0.1 percent of buffer agents, 0.01 to 0.1 percent of antioxidants, 0.05 to 1 percent of adsorbents and 0 to 20 percent of filling agents. The administration mode is interstitial injection; after the passive lymphatic system targeting, the lymph gland can generate the macroscopic blue color. The problems of poor in vitro and vivo physical and chemical property, poor storage stability, preparation flow process complexity and high cost of the micro particle preparation with the lympha targeted function are solved.

The present invention relates to complexes which contain magnetic iron oxide particles in a pharmaceutically acceptable shell, said particles having a diameter of 20 nm to 1 μm with an overall particle diameter / core diameter ratio of less than 6, and to the use of these complexes in magnetic particle imaging (MPI). Particular preference is given to the use of these compositions in examining the gastrointestinal tract, the vascular system of the heart and cranial components, in the diagnosis of arteriosclerosis, infarctions, and tumors and metastases, for example of the lymphatic system.

The present invention is directed to a method for delivering cytokines to the central nervous system and the lymphatic system by way of a tissue innervated by the trigeminal nerve and / or olfactory nerve. Cytokines include tumor necrosis factors, interleukins, interferons, particularly interferon-β and its muteins such as IFN-βser17. Such a method of delivery can be useful in the treatment of central nervous system disorders, brain disorders, proliferative, viral, and / or autoimmune disorders such as Sjogren's disorder.

The present invention relates to the field of diagnostic imaging and provides compositions of ultrasound contrast agents, particularly gas-filled microvesicles suspensions, in combination with vital dyes. The compositions of the invention are advantageously used in the visualization of the lymphatic system, particularly for the detection of the sentinel lymph node or nodes of a tumor.

The invention discloses an application of a compound as a JAK-STAT3 signal passage inhibitor, and particularly relates to an application of a compound with a formula I or pharmaceutically acceptable salt of the compound in the process of preparing an anti-tumor medicament. The application provides a novel treating candidate medicament for a tumor patient, thereby probably further improving the treatment effect on the patient and improving the prognosis of the patient. The compound with the formula I or the pharmaceutically acceptable salt of the compound has the effect on various tumor cells, which indicates that the compound can be used for treating various cancers including cerebral tumor, genitourinary system tumor, lymphatic system tumor, stomach cancer, laryngeal cancer, nasopharyngeal cancer, skin cancer, bone cancer, blood cancer, leukemia, breast cancer and histiocytic lymphoma, non-small cell lung cancer, small-cell lung cancer, lung adenocarcinoma, lung squamous cell cancer, pancreatic cancer, prostatic cancer, liver cancer, epithelial cell cancer and the like. The definition of genes in the formula refers to description for details.

The invention discloses a method for preparing a clinic-level CAR-T cell preparation by minicircle DNA transfection T cells. The method comprises a technology of preparing the clinic-level CAR-T cell preparation by using non-viral minicircle DNA (minicircle DNA, mcDNA) vector to efficiently transfect T cells. The mcDNA transfection technology comprises the design and synthesis of a chimeric antigen receptor (CAR) carried with a target gene, the construction of target gene-CAR parent vector plasmids, the extraction of target gene-CAR-mcDNA vector plasmids, the target gene-CAR-mcDNA vector plasmid transfection T cells, and the clinic-level CAR-T cell preparation prepared by using the mcDNA transfection technology. The invention further discloses a use of the mcDNA transfection technology. The mcDNA transfection technology has the characteristics of high transfection efficiency to mammal T cells, stable expression, stable function, and no effect to cytogene feature. The prepared CAR-T cell preparation has the characteristics of strong targeting property, high killing efficiency and clinic safety. The mcDNA transfection technology can be used for preparing the clinic-level CAR-T cell preparation for treating various solid tumors and blood and lymphatic system tumors.

The invention belongs to the field of pharmaceutical preparation, and relates to a liposome vector system for tumor-targeted drug delivery. The liposome vector system comprises polypeptide containing LyP-1 amino acid sequence of CGNKRTRGC, and liposome, wherein two cysteines are linked through disulfide bonds to form a ring structure of the polypeptide containing the LyP-1 amino acid sequence. With the liposome vector system, the liposome is passively drained into a lymphatic system through subcutaneous tissue space injection or intramuscular injection, and reaches metastatic lymph nodes through a LyP-1-mediated targeting effect. In addition, the liposome vector system can be directly administered by intravenous injection, such that the liposome can reach tumor in situ and lymphatic metastatic tumor through a tumor EPR effect and the LyP-1-mediated targeting effect. The liposome vector system provided by the present invention can be used for targeted drug delivery for diagnosing and treating the tumor in situ and the lymphatic metastatic tumor.

A compression device for exerting pressure on an arm, shoulder, and / or trunk of a patient in need thereof (for example, a patient with hyperalgia or recovering from surgery in which the lymphatic system is affected), including an arm compression hose, a shoulder part for exerting pressure on the shoulder and trunk area, and a band-shaped fastening means for positioning the shoulder part and exerting pressure on the shoulder part. The arm compression hose exerts a pressure that decreases from a maximum pressure at the wrist or hand to a minimum pressure near the shoulder end of the arm, where the minimum pressure is approximately 70% of the maximum pressure. One or more lining pockets can be constructed on the inner lining of the compression device, where each lining pocket can hold one or more compression pads to increase tissue pressure in one or more body areas in need thereof. The compression pads each can have a shape that approximately conforms to the shape of the body part to which it is applied. The shoulder part can also have a shape that approximately conforms to the contour of the shoulder / trunk area to which it is applied. In addition, compression pants can be prepared with lining pockets for receiving compression pads. In one embodiment, compression pants include one or more donut-shaped pads or equivalents thereof that are placed in one or more lining pockets, each of which surrounds one or more osteoma openings.

The invention belongs to the field of molecule biological medicine, and relates to a magnetic polyacrylic acid-modified nanometer pipe and a method for preparing the same. A multi-wall carbon nanometer pipe is modified by polyacrylonitrile and hydrolyzed under acid condition to obtain a polyacrylic acid-modified water-soluble nanometer pipe containing large quantity of carboxyl groups; by the water-phase chemical co-precipitation method, a magnetic ferroferric oxide-polyacrylic acid-modified multi-wall carbon nanometer pipe composite with the diameter of between 10 and 80nm is prepared, and the composite has good lymphotaxis and strong magnetic response; tests show that a medicine carrier can effectively adsorb chemical treatment medicines to a lymphatic system, slowly release the chemical treatment medicines in a metastasis lymph node of a malignant tumor, has good magnetic field positioning effect and obviously inhibits the proliferation and metastasis of the tumor cell of the lymph node. The invention provides a novel intervention means for lymphatic metastasis of the malignant tumor.

The present invention provides methods for the localized delivery of an agent to the lymphatic system, including localized delivery to a lymphatic capillary bed.

The invention belongs to the field of pharmaceutical preparations, and relates to an active targeting liposome carrier system for in situ tumors and lymphatic metastatic tumors. The carrier system is composed of polypeptides and liposomes whose amino acid sequence is CGNKRTRGC sequence of LyP-1. Wherein the LyP-1 sequence polypeptide is connected by two cysteines through a disulfide bond to form a ring structure. The liposome carrier system can passively drain the liposome into the lymphatic system through subcutaneous interstitial injection or intramuscular injection, and target the tumor metastasis lymph node through the mediated effect of LyP-1. The system can also be administered directly via intravenous injection, targeting tumors in situ and lymphatic metastases through tumor EPR effects and LyP-1-mediated effects. The liposome carrier system of the present invention can be used for targeted delivery of drugs for the diagnosis or treatment of tumors in situ and lymphatic metastases.

The invention discloses a health-preserving ceramic material. The health-preserving ceramic material is prepared from the following raw materials including pumice stones, ophicalcitum, magnet, gypsum rubrum, graystones, ruddle, zeolite, mirabilite, graphite, phlogopitum and medical stone. The invention also discloses a health-preserving ceramic container. According to the invention, eleven traditional Chinese medical mineral substances are mixed and proportioned, and are added to china clay after special processing through goldwater ball-milling; and then, multiple times of high-temperature sintering are conducted for producing the ceramic material and the ceramic container. Therefore, the health-preserving ceramic material and the health-preserving ceramic container have an alkalescent property and are capable of generating negative ions, resolving and converting food such as water and alcohol, promoting nutrient uptake, enhancing the metabolism, and effectively inhibiting and rapidly removing toxins in the lymphatic system and gastrointestinal tracts of human bodies, converting macromolecular water into molecular water, improving water absorption of the human bodies, and enhancing the immunity.

The invention discloses a sugar-free compound meal-replacement enzyme solution and a preparation process thereof. The preparation method comprises the following steps: secondarily fermenting the firstly fermented enzyme stoste and a medical material additive, mixing the modified enzyme solution with the meal-replacement agent, the candida utilis and the glycerin, and performing third fermentation to obtain the compound meal-replacement enzyme solution. The compound meal-replacement enzyme solution prepared by the invention has the half-fast meal replacement function in a short time without side effect, is nutrient and delicious, and has the advantages of tonifying spleen and nourishing stomach, adjusting the internal secretion, activating the immunological lymphatic system, nourishing qi and blood, detoxifying, removing edema and losing weight and has the meal-replacement effect.

The invention relates to an anti-tumor drug, taking natural plant ingredients as the essential medicinal ingredients. The anti-tumor drug is an oral drug prepared by the raw materials with the following weight proportions: 10.2 percent of asafetida, 15.3 percent of aspongopus, 10.2 percent of clove, 10.2 percent of costus root, 20.4 percent of rhubarb, 20.4 percent of curcuma longa and 13.3 percent of myrobalan. Based the properties and taste of various drugs, the drug extracts effective ingredients to develop the preparation with convenient taking. The drug provided by the invention is essentially used for treating malignant tumor of digestive tract, malignant tumor of lung, malignant tumor of galactophore, tumor of urogenital system, head-neck malignant tumor, malignant tumor of blood system and malignant tumor of lymphatic system and also has auxiliary treating effect on other malignant tumors.

The invention discloses a traditional Chinese veterinary medicine capable of promoting animal growth, helping digestion and invigorating the spleen. The traditional Chinese veterinary medicine comprises the following raw materials: Radix Codonopsis, Radix Astragali, Poria cocos, bighead atractylodes rhizome, dried orange peel, Chinese yam and brown sugar. A processing method for the traditional Chinese veterinary medicine comprises the following steps: separately crushing the above raw materials into powder with a pulverizer and uniformly mixing the obtained powder according to a prescription. The traditional Chinese veterinary medicine can adjust the functions of the spleen and the stomach, increase feed intake, promote the development of a lymphatic system, improve the immunity of a peripheral immune system and enhance disease resistance.

The invention discloses a method for preparing a spirulina platensis active protein. The method specifically comprises the following steps: putting algae powder into a phosphate buffer liquid and active polypeptides, and performing multigelation so as to obtain a crude protein liquid; adding ammonium sulfate into the crude protein liquid, and performing salting out; putting salted precipitate into a dialysis bag, and performing dialysis in the phosphate buffer liquid; performing a hydroxyapatite adsorption chromatography method on dialyzate, thereby obtaining a pure active protein product. The method has the beneficial effects that active proteins can be extracted by using the method, the extraction efficiency is improved, the yield of the active proteins is increased, the operation is simple, and no special instrument or equipment is needed; the active proteins prepared by using the method are high in purity, bright in color and rich in nutrition, capable of improving lymphocyte activity, improving body immunity through lymphatic systems, improving disease resistance of bodies, removing free radicals in living bodies and promoting hemocyte regeneration of animals, and has remarkable antitumor activity.